Stock Events

Stock Events

Gabather AB 

€0
0
+€0+1,500% Thursday 07:17

Statistics

Day High
0
Day Low
0
52W High
0.01
52W Low
0
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

28MayExpected
Q4 2025
Next
0
0.33
0.67
1
Expected EPS
0
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 5J2.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Astrazeneca
AZN.ST
Mkt Cap2.69T
AstraZeneca operates in the biopharmaceutical sector focusing on various therapeutic areas, including neuroscience, which overlaps with Gabather's focus on CNS disorders.
Biogen
BIIB
Mkt Cap27.62B
Biogen focuses on developing therapies for neurological diseases, directly competing with Gabather's CNS drug development.
Lilly(Eli) &
LLY
Mkt Cap862.01B
Eli Lilly has a strong portfolio in neuroscience, including treatments for psychiatric and neurodegenerative conditions, similar to Gabather's target market.
Novartis
NVS
Mkt Cap279.67B
Novartis offers drugs for neurological conditions, directly competing with Gabather in the CNS pharmaceutical market.
Pfizer
PFE
Mkt Cap149.77B
Pfizer has a diversified portfolio that includes treatments for neurological disorders, positioning it as a competitor in the CNS space.
Merck
MRK
Mkt Cap277.02B
Merck produces medications for health disorders including neurologic conditions, competing with Gabather's CNS focus.
GSK
GSK.LSE
Mkt Cap75.89B
Teva- Pharmaceutical Industries
TEVA
Mkt Cap40.7B
Teva Pharmaceutical specializes in generic and specialty medicines, including CNS treatments, competing with Gabather's market.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson, through its pharmaceutical division Janssen, develops treatments for CNS disorders, aligning as a competitor in the same therapeutic area as Gabather.

About

Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. The company offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer's disease. It focuses on developing GT-002, a pro-cognitive drug candidate for the treatment of Alzheimer's disease, schizophrenia, and major depressive disorders. The company was incorporated in 2014 and is based in Södertälje, Sweden.
Show more...
CEO
Dr. Michael-Robin Witt
Employees
3
Country
Sweden
ISIN
SE0010869552

Listings

MU
DE
5J2.MU
F
DE
5J2.F
ST
SE
GABA.ST

0 Comments

Share your thoughts

FAQ

What is Gabather AB stock price today?▼
The current price of 5J2.MU is €0 EUR — it has increased by +1,500% in the past 24 hours. Watch Gabather AB stock price performance more closely on the chart.
What is Gabather AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Gabather AB stocks are traded under the ticker 5J2.MU.
Is Gabather AB stock price growing?▼
5J2.MU stock has risen by +0% compared to the previous week, the month change is a -15.79% fall, over the last year Gabather AB has showed a -11.11% decrease.
When is the next Gabather AB earnings date?▼
Gabather AB is going to release the next earnings report on May 28, 2026.
What were Gabather AB earnings last quarter?▼
5J2.MU earnings for the last quarter are 0 EUR per share, whereas the estimation was 0 EUR resulting in a +NaN% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Gabather AB have?▼
As of May 04, 2026, the company has 3 employees.
In which sector is Gabather AB located?▼
Gabather AB operates in the Health & Wellness sector.
When did Gabather AB complete a stock split?▼
Gabather AB has not had any recent stock splits.
Where is Gabather AB headquartered?▼
Gabather AB is headquartered in Södertälje, Sweden.